罗沙司他胶囊对比重组人促红素注射液治疗维持性血液透析肾性贫血的有效性及安全性

目的 比较罗沙司他胶囊和重组人促红素注射液（rhEPO）治疗维持性血液透析患者肾性贫血的有效性和安全性。方法 选取2020年9月至2020年11月在本院进行维持性血液透析治疗的40例肾性贫血患者，采用随机抽签法将其分为试验组和对照组，每组各20例。试验组使用罗沙司他胶囊治疗，对照组使用rhEPO治疗，研究进行12周。比较两组患者的红细胞计数（RBC）、血红蛋白（Hb）、红细胞比容（Hct）、铁蛋白（SF）、转铁蛋白（TRF）、转铁蛋白饱和度（TS）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）及不良反应。结果 治疗前，两组的RBC、Hb、Hct、SF、TRF、TS、TG、TC、LDL比较，差异均无统计学意义 (均P>0.05)，治疗12周后，试验组的RBC、Hb、Hct、SF、TRF、TS均高于对照组，而试验组的TG、TC、LDL均低于对照组，差异均有统计学意义（均P<0.05）。两组均无严重不良反应出现。结论 罗沙司他胶囊可以明显改善维持性血液透析患者的肾性贫血，还可降低血脂水平，改善患者铁的利用率，其药效起效快，耐受性好，安全性较高，对肾性贫血患者是一种很好的选择。

The efficacy and safety of losarta capsule in the treatment of renal anemia in patients with maintenance hemodialysis compared with recombinant human erythropoietin injection

Objective  To compare the efficacy and safety of losarta capsule and recombinant human erythropoietin injection (rhEPO) in the treatment of renal anemia in maintenance hemodialysis patients.Methods  From September 2020 to November 2020, 40 patients with renal anemia who underwent maintenance hemodialysis in our hospital were randomly divided into experimental group (20 cases) and control group (20 cases). The experimental group was treated with losartan capsules, and the control group was treated with erythropoietin. The experiment lasted for 12 weeks. Red blood cell count (RBC), hemoglobin (Hb), erythrocyte volume (Hct), ferritin (SF), transferrin (TRF), transferrin saturation (TS), triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) and adverse reactions were compared between two groups.Results  Before treatment, there were no statistically significant differences in RBC, Hb, Hct, SF, TRF, TS, TG, TC and LDL between the two groups (all P>0.05). After 12 weeks of treatment, RBC, Hb, Hct, SF, TRF and TS in the experimental group were higher than those in the control group, while TG, TC and LDL in the experimental group were lower than those in the control group. The differences were statistically significant (all P<0.05). There were no serious adverse reactions in two groups.Conclusions  Rosalrestat capsule can significantly improve renal anemia in maintenance hemodialysis patients, significantly reduce blood lipid level, improve the utilization rate of iron in patients, with fast onset, good tolerance and high safety, which is a good choice for patients with renal anemia.